Local, Real-World Data
Kidney biopsy RNA sequencing data from Taiwanese patients, representing the local disease spectrum and genetic background, integrated with multi-omics data from over 1,000 participants.
A Complete Translational Loop
TRTOI follows a complete translational research pipeline, from clinical specimens and multi-omics analysis to tissue- and specific transgenic mouse models, with findings translated back into clinical practice.
Multi-Layered Omics Integration
Integrating genomic, transcriptomic, epigenomic, epitranscriptomic (m6A), proteomic, and other multi-omics data to provide a comprehensive view of kidney disease mechanisms.
Recognized at Home and Abroad
Findings published in high-impact journals such as JASN, CJASN, Kidney Int, and JCI Insight, and selected as a 2024 Best of ASN Journals article.
Cross-Disciplinary Collaboration
Integrating expertise in nephrology, urology, pathology, radiology, bioinformatics, biobanking, and big data to advance multidisciplinary kidney disease research.
Strong Demand and Industry Value
The growing demand for insights into kidney disease mechanisms and non-invasive biomarkers positions TRTOI as a valuable resource for translational research and industry partnerships.
Three Pillars of Translational Medicine
TRTOI's translational research framework is built on three key strengths:
- Rich, complete clinical data—Comprehensive clinical phenotyping integrated with multi-omics analyses and validation across independent cohorts.
- Convincing animal experiments—using tissue- and cell-specific, inducible transgenic mouse models to establish the causal roles of candidate genes and support the development of small-molecule inhibitors and therapeutic antibodies.
- A sound molecular mechanism—using cell experiments to explore molecular pathways and define the pathophysiological mechanisms underlying kidney disease.